Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Compared to Chemotherapy in Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Express PD-L1 (CPS ≥10)
Wed November 14, 2018 6:45 AM|Business Wire|About: MRK
Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments
08/05/2019
Failure to respond to migraine preventive treatments is a common occurrence; internationally it is estimated that more than 40% of patients who use migraine preventive medications have a history of failure or switching treatments(1)
INDIANAPOLIS, Aug. 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)
CMS Grants New Technology Add-On Payment for Inpatient Use of AZEDRA® (iobenguane I 131)
Tue August 6, 2019 8:30 AM|GlobeNewswire|About: PGNXGlobeNewswire
NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (PGNX),
https://www.progenics.com/product-pipeline/overview/
Merck Begins Rolling Submission of Licensure Application for V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration
Tue November 13, 2018 4:35 PM|Business Wire|About: MRK
Lyfebulb Partners with Celgene to Inspire Patient-Driven Innovation in the Management of Multiple Sclerosis
Wed November 14, 2018 7:58 AM|PR Newswire|About: CELG
NEW YORK, Nov. 14, 2018 /PRNewswire/
November 14, 2018
AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress
NORTH CHICAGO, Ill., Nov. 14, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV)
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Thu August 1, 2019 7:00 AM|PR Newswire|About: BMY, NKTR
SAN FRANCISCO, Aug. 1, 2019 /PRNewswire/ -- Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY)
Two Phase 3 Studies of the Triple Combination of VX-659, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis
Tue November 27, 2018 8:00 AM|Business Wire|About: VRTX
AstraZeneca Presents Clinical Research Advances for Blood Cancer Patients at 2018 American Society of Hematology Annual Meeting
Tue November 27, 2018 7:00 AM|Business Wire|About: AZN
Wed August 14, 2019 8:00 AM|Business Wire|About: AZN
Designation based on positive results from two Phase III trials
WILMINGTON, Del.--(BUSINESS WIRE)
Pfizer Receives Six Months Pediatric Exclusivity for LYRICA® (pregabalin)
Tue November 27, 2018 3:01 PM|Business Wire|About: PFE
Bayer's hemophilia A treatment Jivi OK'd in Europe
Nov. 27, 2018 11:15 AM ET|About: Bayer A.G. ADR (BAYRY)|By: Douglas W. House, SA News Editor
Medtronic's Valiant Navion stent CE Mark'd
Nov. 13, 2018 10:23 AM ET|About: Medtronic plc (MDT)|By: Douglas W. House, SA News Editor
Sobi to acquire U.S. rights to AstraZeneca's Synagis and half interest in MEDI8897 for $1.5B
Nov. 13, 2018 8:34 AM ET|About: AstraZeneca Group plc (AZN)|By: Douglas W. House, SA News Editor
Ebola clinical trial to begin in DRC
Nov. 13, 2018 4:49 AM ET|By: Yoel Minkoff, SA News Editor
Helen Branswell
Enanta’s HCV Collaboration Partner AbbVie receives Approval by the European Commission for MAVIRET™ (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve HCV Patients with Compensated Cirrhosis
Fri August 2, 2019 8:51 AM|Business Wire|About: ENTA
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (ENTA)
Real-World Evidence on Patients Aged 80 and Older Presented From ARISTOPHANES, the Largest Real-World Data Study Evaluating Oral Anticoagulants Among Patients with Non-Valvular Atrial Fibrillation
Eliquis® (apixaban) was associated with lower rates of stroke or systemic embolism and major bleeding in elderly patient populations when compared to rivaroxaban and dabigatran
(PRINCETON, N.J. & NEW YORK) November 11, 2018 – The Bristol-Myers Squibb-Pfizer Alliance
New Data from Investigational Study of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
Fri November 9, 2018 6:45 AM|Business Wire|About: MRK
TOKYO & KENILWORTH, N.J.--(BUSINESS WIRE)-- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Merck (MRK), known as MSD outside the United States and Canada,
FARXIGA Significantly Reduced Hospitalization for Heart Failure or CV Death in a Broad Patient Population with Type 2 Diabetes in the Landmark DECLARE-TIMI 58 Trial
Sat November 10, 2018 4:45 PM|Business Wire|About: AZN
Lynparza Phase III PROfound trial in HRR* mutation-selected metastatic castration-resistant prostate cancer met primary endpoint
PUBLISHED7 August 2019
7 August 2019 07:00 BST
AstraZeneca and MSD’s Lynparza met the primary endpoint of significantly increasing the time patients selected for BRCA1/2 or ATM mutations live without radiographic disease progression vs. standard of care treatment
Only PARP inhibitor with positive Phase III results in four different cancer types (ovarian, breast, pancreatic and prostate)
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc
AstraZeneca and Merck's Lynparza shows treatment benefit in late-stage prostate cancer study
Aug. 7, 2019 7:04 AM ET|About: AstraZeneca PLC (AZN)|By: Douglas W. House, SA News Editor
Lynparza Phase III PAOLA-1 trial met primary endpoint as 1st-line maintenance treatment with bevacizumab for advanced ovarian cancer
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada)
Amgen Presents Results Highlighting The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In The Longest Duration Study Of A PCSK9 Inhibitor To Date At AHA Scientific Sessions 2018
Mon November 12, 2018 4:00 PM|PR Newswire|About: AMGN
THOUSAND OAKS, Calif., Nov. 12, 2018 /PRNewswire/ -- Amgen (AMGN)
Mirati's mocetinostat + AstraZeneca's Imfinzi show positive effect in mid-stage lung cancer study
Nov. 9, 2018 9:30 AM ET|About: AstraZeneca Group plc (AZN)|By: Douglas W. House, SA News Editor
ODYSSEY OUTCOMES Investigators Highlight at AHA that Praluent® (alirocumab) Injection Was Associated with Fewer Deaths from Any Cause
Sun November 11, 2018 8:14 AM|PR Newswire|About: REGN
TARRYTOWN, N.Y. and PARIS, Nov. 11, 2018 /PRNewswire/ --
Amgen Announces Presentation Of Research Reinforcing The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In High-Risk Patients At AHA Scientific Sessions 2018
Mon November 5, 2018 4:00 PM|PR Newswire|About: AMGN
Mon September 9, 2019 3:20 AM|PR Newswire|About: LLY
PR Newswire
INDIANAPOLIS, Sept. 9, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY)
Dupixent® (dupilumab) Showed Positive Topline Results in Phase 3 Trial of Children Aged 6 to 11 Years with Severe Atopic Dermatitis
Tue August 6, 2019 1:04 AM|PR Newswire|About: REGN
TARRYTOWN, N.Y. and PARIS, Aug. 6, 2019 /PRNewswire/ --
U.S. FDA submission for children planned for 4Q 2019
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi
Mon September 16, 2019 6:00 AM|GlobeNewswire|About: AMRN
Millions of Patients on Statins with Elevated Triglycerides Are at Risk of Cardiovascular Events, Such as Heart Attack, Stroke or Death
Icosapent Ethyl Recognized as Only Non-LDL-Cholesterol Lipid Management Treatment with Cardiovascular Risk Reduction Outcomes Results
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (AMRN)
Lilly and NextCure Announce Collaboration to Discover and Develop Novel Immuno-Oncology Medicines
Mon November 5, 2018 4:30 PM|PR Newswire|About: LLY
August 12, 2019 at 10:01 AM EDT
TARRYTOWN, N.Y., Aug. 12, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
Genentech’s Tecentriq® (ATEZOLIZUMAB) Plus Platinum-based Chemotherapy Reduced the Risk of Disease Worsening or Death in People With Previously Untreated Advanced Bladder Cancer
Mon August 5, 2019 1:00 AM|Business Wire|About: RHHBY
– IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in previously untreated advanced bladder cancer –
– Data will be shared with health authorities globally, including the U.S. Food and Drug Administration (FDA) –
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY)
Bavarian Nordic launches Phase 1/2 study of prime/boost vaccine CV301 in colorectal and pancreatic cancers
Nov. 2, 2018 11:47 AM ET|By: Douglas W. House, SA News Editor
FDA OKs expanded use for Novartis' Promacta
Nov. 16, 2018 4:43 PM ET|About: Novartis AG (NVS)|By: Douglas W. House, SA News Editor
European advisory group backs ViiV Healthcare's Tivicay + lamivudine in HIV-1
Nov. 19, 2018 7:14 AM ET|By: Douglas W. House, SA News Editor
August 08, 2019
Gilead Sciences Statement on U.S. Food and Drug Administration Advisory Committee’s Recommendation on Descovy for PrEP™
FOSTER CITY, Calif.--(BUSINESS WIRE)--Aug. 7, 2019-- Gilead Sciences, Inc. (NASDAQ: GILD
Fri August 9, 2019 7:00 AM|Business Wire|About: AZN
TAGRISSO is the only medicine demonstrating statistically-significant overall survival benefit in this setting. Also increased the time patients with central nervous system metastases lived without disease progression
WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca
Glaxo files U.S. marketing application for expanded use of Nucala
Nov. 19, 2018 7:46 AM ET|By: Douglas W. House, SA News Editor
U.S. FDA Approves DAURISMO™ (glasdegib) for Adult Patients with Newly-Diagnosed Acute Myeloid Leukemia (AML) for Whom Intensive Chemotherapy is Not an Option
Wed November 21, 2018 1:40 PM|Business Wire|About: PFE
AbbVie Receives US FDA Accelerated Approval for VENCLEXTA® (venetoclax) for Treatment of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy
Wed November 21, 2018 2:14 PM|PR Newswire|About: ABBV
Janssen Announces U.S. FDA Accelerated Approval for SIRTURO® (bedaquiline) as Part of Combination Therapy to Treat Adolescents with Pulmonary Multidrug-Resistant Tuberculosis
Label expansion marks important milestone in Johnson & Johnson’s pediatric research and development program for bedaquiline
TITUSVILLE, NJ, August 9, 2019 — The Janssen Pharmaceutical Companies of Johnson & Johnson
Analysts Take Action on Health Care Stocks
JPMorgan initiates coverage of BeiGene, Brookline Capital Markets starts covering Celsion and Cellectar Biosciences
November 21, 2018
UPDATE - BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium
November 20, 2018 | About: BCTXF +0% MRK +0%
Note: This Press Release contains amendments to the press release previously issued on Nov. 19, 2018
Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer
Wed August 7, 2019 7:05 AM|GlobeNewswire|About: AZN, MYGN
SALT LAKE CITY, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics (MYGN), Inc. (NASDAQ: MYGN)
Tue August 13, 2019 7:00 AM|PR Newswire|About: REGNQ2: 08-06-19 Earnings Summary
EPS of $6.02 beats by $0.60 Revenue of $1.93B (20.25% Y/Y) beats by $131.71M
TARRYTOWN, N.Y., Aug. 13, 2019 /PRNewswire/ -
Priority Review Granted to BeiGene’s New Drug Applications for Zanubrutinib and Tislelizumab in China
Thu November 15, 2018 7:00 AM|GlobeNewswire|About: BGNE
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) Tablets for the Treatment of Hepatocellular Carcinoma in Adults Previously Treated with Sorafenib
Thu November 15, 2018 1:32 AM|Business Wire|About: EXEL
FDA Grants Breakthrough Therapy Designation to ADCETRIS® (Brentuximab Vedotin) for Frontline Peripheral T-Cell Lymphomas
Thu November 15, 2018 8:00 AM|Business Wire|About: SGEN
New Approvals Allow Chronic Pain Sufferers to Try Abbott's Non-Opioid Pain Therapy Before Getting Device Implant
Thu November 15, 2018 9:00 AM|PR Newswire|About: ABT
CVS Health Teams Up with Philadelphia Job Corps, Philadelphia Works and Philadelphia Youth Network to Open New Mock Pharmacy for Aspiring Pharmacy Technicians
Thu November 15, 2018 8:00 AM|PR Newswire|About: CVS
PHILADELPHIA, Nov. 15, 2018 /PRNewswire/
Novo Nordisk's PIONEER 9 trial successfully meets primary endpoints
Nov. 23, 2018 7:40 AM ET|About: Novo Nordisk A/S (NVO)|By: Mamta Mayani, SA News Editor
European Commission Approves Spark Therapeutics’ LUXTURNA® (voretigene neparvovec), a One-time Gene Therapy for Inherited Retinal Disease Caused by Confirmed Biallelic RPE65 Mutations
Fri November 23, 2018 1:15 AM|GlobeNewswire
Spark Therapeutics (ONCE) will manufacture and supply LUXTURNA for Novartis, while Novartis has exclusive rights to pursue development, registration and commercialization in all other countries outside the U.S.
PHILADELPHIA, Nov. 23, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics
Decision represents the fifth European approval in five years
August 13, 2019 07:08 AM Eastern Daylight Time
BEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson
AstraZeneca's Fasenra an Orphan Drug in U.S. for rare type of blood vessel inflammation
Nov. 26, 2018 6:46 AM ET|About: AstraZeneca Group plc (AZN)|By: Douglas W. House, SA News Editor
Tue August 27, 2019 4:16 PM|Business Wire|About: BMY
ViiV Healthcare's HIV med Juluca OK'd in Japan
Nov. 26, 2018 7:33 AM ET|By: Douglas W. House, SA News Editor
Lilly to Present Clinical Data for Verzenio® (abemaciclib) and Real-World Evidence across HR+, HER2- Metastatic Breast Cancer at 2018 SABCS
Thu November 29, 2018 6:45 AM|PR Newswire|About: LLY
European Commission Approves Merck’s DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients
Wednesday, November 28, 2018 4:30 pm EST KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK)
Eyenovia's micro-dose latanoprost shows positive effect in mid-stage study
Nov. 28, 2018 4:33 PM ET|By: Douglas W. House, SA News Editor
Amgen opts in on second cancer program with Nuevolution
Nov. 29, 2018 6:55 AM ET|About: Amgen Inc. (AMGN)|By: Douglas W. House, SA News Editor
Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia
Thu November 29, 2018 7:01 AM|PR Newswire|About: ALKS
Varian Halcyon Treatment System Receives China NMPA Approval
Wed November 28, 2018 4:10 PM|PR Newswire|About: VAR
GW Pharma's Epidiolex successful in second late-stage study in Dravet syndrome
Nov. 26, 2018 7:16 AM ET|About: GW Pharmaceuticals plc (GWPH)|By: Douglas W. House, SA News Editor
Opthea completes enrollment in mid-stage study of OPT-302 in wet AMD
Nov. 26, 2018 11:48 AM ET|About: Opthea Limited ADR (CKDXY)|By: Douglas W. House, SA News Editor
Zymeworks and BeiGene Announce License and Collaboration Agreement for Zymeworks’ HER2-Targeted Therapeutic Candidates, ZW25 and ZW49, in Asia-Pacific and Research and License Agreement for Zymeworks’ Azymetric™ and EFECT™ Platforms Globally
Tue November 27, 2018 6:30 AM|Business Wire|About: BGNE, ZYME
FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2)
Mon November 26, 2018 7:16 PM|GlobeNewswire|About: LOXO
Celgene Corporation and bluebird bio Complete Enrollment of Pivotal KarMMa Study of anti-BCMA Car T Cell Therapy bb2121 in Patients with Relapsed and Refractory Multiple Myeloma
Tue November 27, 2018 7:30 AM|Business Wire|About: BLUE, CELG
SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (CELG) and bluebird bio, Inc. (BLUE)
November 6, 2018
AbbVie Announces HUMIRA® (adalimumab) Global Patent License with Momenta
NORTH CHICAGO, Ill., Nov. 6, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV)
FDA OKs Bristol-Myers Squibb's Empliciti for treatment-resistant myeloma
Nov. 6, 2018 4:51 PM ET|About: Bristol-Myers Squibb C... (BMY)|By: Douglas W. House, SA News Editor
Two Studies Measure Performance of ACUVUE OASYS with Transitions Light Intelligent Technology Contact Lenses in Simulated Sunlight, Day and Night Driving Conditions
Tue November 6, 2018 9:19 AM|PR Newswire|About: JNJ
Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting
Tue November 6, 2018 8:01 AM|PR Newswire|About: ALKS
Sorrento Therapeutics Anti-CEA CAR-T Demonstrates Significant Therapeutic Activity With Increased Overall Survival in Pancreatic Cancer Patients With Liver Metastases
Tue November 6, 2018 8:01 AM|GlobeNewswire|About: SRNE
SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (SRNE) ("Sorrento")
TUV Rheinland OpenSky helps insulin pump by Insulet achieve cybersecurity certification by DTSec
Tue November 6, 2018 11:59 AM|GlobeNewswire|About: PODD
COLOGNE, Germany and LITTLETON, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE)
Aug. 13, 2019 2:31 PM ET | About: Insulet Corporation (PODD)
Thu August 15, 2019 4:10 PM|Business Wire|About: RHHBY
– First FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread to the brain –
– Genentech’s first FDA-approved tumor-agnostic medicine –
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY)
Medtronic Q2 revenues up 6%; non-GAAP EPS up 14%; raises revenue growth guidance
Nov. 20, 2018 7:10 AM ET|About: Medtronic plc (MDT)|By: Mamta Mayani, SA News Editor
AbbVie to Highlight Breadth of Innovative Science and Ongoing Commitment to Blood Cancer Patients with New Data From Studies of Ibrutinib and Venetoclax at 2018 American Society of Hematology Annual Meeting & Exposition
Tue November 20, 2018 8:32 AM|PR Newswire|About: ABBV
FDA accepts Allergan's sNDA for AVYCAZ
Nov. 20, 2018 7:54 AM ET|About: Allergan plc (AGN)|By: Mamta Mayani, SA News Editor
Sandoz and Pear Therapeutics announce launch of reSET® for treatment of patients with Substance Use Disorder
Mon November 19, 2018 6:46 PM|GlobeNewswire|About: NVS
Novartis' Entresto beats enalapril in heart failure study
Nov. 12, 2018 7:46 AM ET|About: Novartis AG (NVS)|By: Douglas W. House, SA News Editor
FDA Safety Study of Unloading the Left Ventricle for 30 Minutes Prior to Reperfusion in Heart Attack Patients is Safe and Feasible
Abiomed will initiate pivotal randomized controlled trial with FDA
CHICAGO--(BUSINESS WIRE)--Nov. 11, 2018-- Abiomed (NASDAQ: ABMD)
Singapore National Eye Centre, Singapore Eye Research Institute And Johnson & Johnson Vision Set Sights On Halting Global Myopia Epidemic
Mon November 12, 2018 1:30 AM|PR Newswire|About: JNJ
SINGAPORE, Nov. 12, 2018 /PRNewswire/
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Hepatocellular Carcinoma (HCC) Who Have Been Previously Treated with Sorafenib
Fri November 9, 2018 4:21 PM|Business Wire|About: MRK
Illumina’s Growth Shows No Signs of Slowing Down
Illumina's recent acquisition of Pacific Biosciences of California strongly strengthens its product offering and ensures growth for years to come
Thu August 15, 2019 4:01 PM|Business Wire|About: GILD, GLPG
FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) and Galapagos NV (GLPGF) (Euronext & NASDAQ: GLPG)
AcelRx announces FDA approval of DSUVIA™
REDWOOD CITY, Calif., Nov. 2, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX),
U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC
Fri November 2, 2018 4:42 PM|Business Wire|About: PFE
Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology
Fri November 2, 2018 5:27 PM|PR Newswire|About: NVS
EAST HANOVER, N.J., Nov. 2, 2018 /PRNewswire/
August 14, 2019 at 7:00 AM EDT Back
TARRYTOWN, N.Y., Aug. 14, 2019 /PRNewswire/ --
Adding evinacumab reduced LDL cholesterol by 49% in patients with homozygous familial hypercholesterolemia, compared to lipid-lowering therapies alone
Evinacumab was generally well-tolerated, and all evinacumab patients completed the six-month treatment period
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN
Tue August 27, 2019 8:30 AM|Business Wire|About: ALXN
- SOLIRIS® (eculizumab) is the first and only approved medication for NMOSD in Europe -
- 98% of adult anti-aquaporin-4 (AQP4) antibody-positive patients treated with SOLIRIS were relapse free compared to 63% receiving placebo at 48 weeks -
BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (ALXN)
BeiGene to Present Clinical Data on PARP Inhibitor Pamiparib at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
Mon November 5, 2018 7:00 AM|GlobeNewswire|About: BGNE
Amgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO® (Blinatumomab) In Patients With Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
Fri November 16, 2018 9:00 AM|PR Newswire|About: AMGN
Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-Expressing Peripheral T-Cell Lymphomas
Fri November 16, 2018 10:52 AM|Business Wire|About: SGEN
Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo® (nivolumab) Plus Low-Dose Yervoy® (ipilimumab) as First-Line Treatment for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma
Thu November 15, 2018 4:30 PM|Business Wire|About: BMY
ACUVUE OASYS with Transitions Light Intelligent Technology Named Among TIME's 'Best Inventions of 2018'
Fri November 16, 2018 7:03 AM|PR Newswire|About: JNJ
JACKSONVILLE, Fla., Nov. 16, 2018 /PRNewswire/
Agilent Expands Cell Analysis R&D Capabilities in Ireland
Fri November 16, 2018 11:00 AM|Business Wire|About: A
BeiGene's pamiparib shows positive action in Phase 1/2 brain cancer study
Nov. 16, 2018 7:56 AM ET|About: BeiGene (BGNE)|By: Douglas W. House, SA News Editor
FDA Grants Priority Review to Genentech’s Tecentriq in Combination with Abraxane for the Initial Treatment of People with PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
Tue November 13, 2018 1:06 AM|Business Wire|About: RHHBY
JPOD @ Philadelphia officially launched at Pennovation Works
JPOD @ Philadelphia, the first of its kind in the nation, is a networking hub that includes a secure telecommunications conferencing system to connect regional innovators to the J&J Innovation and JLABS network. It's about leveraging the talent-particularly in the health sciences-that is rampant and unique to Philadelphia, as well as boosting it.
READ MORE ›
November 13, 2018
Gilead's GS-9674 shows positive action in mid-stage NASH study
Nov. 9, 2018 8:35 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W. House, SA News Editor
Akcea up 3% on positive AKCEA-APO(a)-Lrx data
Nov. 12, 2018 2:08 PM ET|About: Akcea Therapeutics (AKCA)|By: Douglas W. House, SA News Editor
collaboration partner Novartis (NVS)
Intuitive Surgical Is Ironman For Doctors
Nov. 12, 2018 9:02 AM ET|8 comments | About: Intuitive Surgical, Inc. (ISRG)
Bristol-Myers Squibb and Infinity Pharmaceuticals Announce a New Clinical Collaboration to Evaluate Opdivo (Nivolumab) in Combination with IPI-549 in Urothelial Cancer
Trulicity® (dulaglutide) demonstrates superiority in reduction of cardiovascular events for broad range of people with type 2 diabetes
Mon November 5, 2018 6:45 AM|PR Newswire|About: LLYPR Newswire
INDIANAPOLIS, Nov. 5, 2018 /PRNewswire/
Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease
Intercept Announces New OCA Data to be Presented at The Liver Meeting® 2018
Mon November 5, 2018 7:00 AM|GlobeNewswire|About: ICPT
Lilly's Jardiance reduced heart failure hospitalization risk in real-world study
Nov. 5, 2018 7:55 AM ET|By: Douglas W. House, SA News Editor
Seattle Genetics Submits Supplemental Biologics License Application for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas
Mon November 5, 2018 8:00 AM|Business Wire|About: SGEN
Abiomed Announces Q2 FY 2019 Record Revenue of $182 Million, up 37% Over Prior Year
Thu November 1, 2018 7:00 AM|GlobeNewswire|About: ABMD
DANVERS, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (ABMD)
AbbVie Receives European Commission Approval of VENCLYXTO® (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
Thu November 1, 2018 12:02 AM|PR Newswire|About: ABBV
Vertex Pharma's Symkevi OK'd in Europe
Nov. 1, 2018 7:05 AM ET|About: Vertex Pharmaceuticals... (VRTX)|By: Douglas W. House, SA News Editor
The Landmark DECLARE-TIMI 58 Cardiovascular Outcomes Trial of FARXIGA in Patients with Type 2 Diabetes to Be Featured at AHA 2018
Thu November 1, 2018 7:00 AM|Business Wire|About: AZN
WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca
Novo Nordisk Q3 revenues up 4%;
Nov. 1, 2018 6:24 AM ET|About: Novo Nordisk A/S (NVO)|By: Mamta Mayani, SA News Editor
TG Therapeutics up 7% on positive umbralisib + ublituximab data
Nov. 1, 2018 11:04 AM ET|By: Douglas W. House, SA News Editor
The overall response rate (ORR) was 89% (n=8/9) in BTK-refractory chronic lymphocytic leukemia (CLL) patients receiving the combination of umbralisib + ublituximab + Merck's (MRK +0.1%) Keytruda (pembrolizumab).
Copyright © 2018 seeking biotech alpha - All Rights Reserved. City Photos from Pixabay
Powered by GoDaddy Website Builder